CD274 and neoplasm: The assessment of PD-L1 expression on a tumor specimen by immunohistochemistry has been acknowledged as a prognostic and predictive biomarker for tailoring use of PD-1/PD-L1 targeting agents in solid cancers, including SCCHN [77].